Orally disintegrating tablet compositions of lamotrigine
View Patent ↗The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with bipolar patients.
1. An ODT consisting essentially of:
lamotrigine microcapsules comprising 25 or 200 mg of lamotrigine crystals having an average particle size of about 1-50 μm, coated with a taste-masking layer consisting of ethylcellulose, wherein the average coating weight of said microcapsules is about 15% of the total weight of the microcapsules; and
rapidly dispersing granules comprising a granulate of crospovidone and mannitol in a ratio ranging from about 90/10 to about 99/1, wherein the rapidly dispersing granules are about 60% to 70% of the total weight of the ODT; and
an additional disintegrant comprising crospovidone;
wherein after a single oral administration said ODT provides;
a C max in the range of 0.276 to 0.482 ng/mL of lamotrigine, an AUC 0-24 in the range of 4.87 to 8.17 ng·hr/mL of lamotrigine, or
both a C max in the range of 0.276 to 0.482 ng/mL of lamotrigine and an AUC 0-24 in the range of 4.87 to 8.17 ng·hr/mL of lamotrigine,
if the total amount of lamotrigine in the ODT is 25 mg, or
a C max in the range of 2.21 to 3.95 ng/mL of lamotrigine, an AUC 0-24 in the range of 36.0 to 63.6 ng·hr/mL of lamotrigine, or
both a C max in the range of 2.21 to 3.95 ng/mL of lamotrigine and an AUC 0-24 in the range of 36.0 to 63.6 ng·hr/mL of lamotrigine,
if the total amount of lamotrigine in the ODT is 200 mg.
2. The ODT of claim 1 , wherein the ethylcellulose has a viscosity of about 90-110 cps when tested in an Ubbelohde viscometer as a 5 weight % solution in 80:20 toluene/ethanol at 25° C.
3. The ODT of claim 1 , wherein the ODT substantially disintegrates within about 30 seconds after administration in the oral cavity of the patient.
4. The ODT of claim 1 , wherein the ODT disintegrates within about 30 seconds when tested by the <USP 701> Disintegration Test.
5. The ODT of claim 1 , wherein the ODT releases about 70% or more of the total dose of lamotrigine upon entering the stomach of the patient.
6. The ODT of claim 1 , wherein the ODT releases about 70% or more of the lamotrigine in 30 min when tested for dissolution using United States Pharmacopoeia Apparatus 2 (paddles @ 75 rpm in 900 mL of 0.01N HCl buffer).
7. A method of treating a mood disorder, or treating or preventing seizures comprising administering to a patient in need thereof a therapeutically effective amount of the ODT of claim 1 .
8. The ODT of claim 1 wherein said ODT provides a C max in the range of 0.276 to 0.482 ng/mL of lamotrigine, if the total amount of lamotrigine in the ODT is 25 mg.
9. The ODT of claim 1 wherein said ODT provides an AUC 0-24 in the range of 4.87 to 8.17 ng·hr/mL of lamotrigine, if the total amount of lamotrigine in the ODT is 25 mg.
10. The ODT of claim 1 wherein said ODT provides a C max in the range of 0.276 to 0.482 ng/mL of lamotrigine and an AUC 0-24 in the range of 4.87 to 8.17 ng·hr/mL of lamotrigine, if the total amount of lamotrigine in the ODT is 25 mg.
11. The ODT of claim 1 wherein said ODT provides a C max in the range of 2.21 to 3.95 ng/mL of lamotrigine, if the total amount of lamotrigine in the ODT is 200 mg.
12. The ODT of claim 1 wherein said ODT provides an AUC 0-24 in the range of 36.0 to 63.6 ng·hr/mL of lamotrigine, if the total amount of lamotrigine in the ODT is 200 mg.
13. The ODT of claim 1 wherein said ODT provides a C max in the range of 2.21 to 3.95 ng/mL of lamotrigine and an AUC 0-24 in the range of 36.0 to 63.6 ng·hr/mL of lamotrigine, if the total amount of lamotrigine in the ODT is 200 mg.